Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Restoring Ovulation in Youth and Adults With PCOS
NCT05819853Phase 3Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2023
- Primary completion
- Feb 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of semaglutide in polycystic ovary syndrome (PCOS) and obesity (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Change in ovulation frequency at 14 months. Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
polycystic ovary syndrome (PCOS)obesity
Beyond the preview
Go deeper on NCT05819853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819853.